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Clinical Considerations of
Dimethyl Sulfoxide
Linda K. Wong, BA, DVM*
Eric L. Reinertson, DVM, MS**
INTRODUCTION
Din1ethyl sulfoxide (DMSO) has been
heralded as a "miracle" drug capable of a wide
range of therapeutic capabilities. While its bi-
ological actions are indeed diverse, one must
reserve judgement on the attributes of DMSO
until further clinical studies involving the spe-
cific actions of DMSO are conducted. It is
clear that DMSO has amazing properties that
certainly could be useful in the treatment of
many medical disorders.
DMSO is a naturally occurring organic
compound. All plant matter of marine origin
contain trace quantities of DMSO. 1 The phy-
toplankton growing near the ocean surface
constantly expell volatile dimethyl sulfide
(DMS) which evaporates to the ozone layer of
the atmosphere and is oxidized to dimethyl
sulfoxide. DMSO then reaches the earth in
the form of rain. In 1963, studies of DMSO
indicated that this by-product of paper manu-
facturing had remarkable properties, includ-
ing: rapid penetration of skin, transport of
other drugs across biological membranes, lo-
cal anesthetic properties, reduction of swelling
and promotion of healing. 4
The first Investigational New Drug exemp-
tion (IND) for the study of DMSO in humans
was filed with the Food and Drug Administra-
tion in 1963.4 Unfortunately, the lack of con-
trolled studies and widespread use of DMSO
up to 1965 led to many unorthodox treatment
regimes which included DMSO. In Novem-
ber of 1965 the FDA terminated all clinical
studies of DMSO because toxicological stud-
ies indicated that DMSO caused changes in
the refractive index in the lens of the eye in
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experimental animals. In 1966 and 1968 the
FDA revised its policy on DMSO to allow
clinical evaluation of DMSO in certain spe-
cific medical conditions, and in 1980 the FDA
revoked the regulation establishing specific re-
quirements for the clinical testing of DMSO
in humans. 4 Although the restrictions regard-
ing clinical research of DMSO have been re-
laxed, the initial enthusiasm of the clinical use
of DMSO has not resurfaced. This is unfortu-
nate in light of the many potentially beneficial
uses of DMSO in the medical field.
CHEMISTRY OF DMSO
Dimethyl sulfoxide, (CH3)3S04, is a dipo-
lar, organic compound, with a molecular
weight of 78.13. 2 DMSO is a stable, colorless,
nonvolatile, hydroscopic, highly associated
liquid with a sulfur-like smell and a slightly
bitter taste. 5
DMSO is completely miscible with water in
any proportion and acts as the acceptor of hy-
drogen bonds. DMSO can complex with a
multitude of compounds including: metal ca-
tions, various drugs, and components of tis-
sue, blood, plasma, spinal fluid, etc.
DMSO can act as both an oxidizing and a
reducing agent. When acting as an oxidant,
DMSO is reduced to dimethyl sulfide (DMS)
and when acting as a reducing agent, DMSO
is oxidized to dimethyl sulfone (DMS02).
METABOLISM OF DMSO
Regardless of the route of administration of
DMSO, a remarkable amount of radioactive
DMSO is found in the plasma after only 30
minutes. Cutaneous administration of
DMSO generally results in lower serum levels
than when DMSO is administered per os or
intravenously.7 Maximal blood concentrations
of DMSO applied cutaneously are reached in
2 hours.
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An oral dose of 1g/kg-body weight results
in peak plasma concentrations in 4 - 6 hours,
and detectable levels persisted for 400 hours.
DMSO administered intravenously at the
same dosage achieves higher plasma levels
and is rapidly distributed throughout all tis-
sues. 7
DMSO is metabolized in animals and man
to form dimethyl sulfide (DMS) and dimethyl
sulfone (DMS02 ). DMSO and DMS02 are
present in all examined tissues including both
hard (i. e. lens and bone) and soft tissues. 3 Un-
altered DMSO is by far the most prevalent in
tissues, blood, feces' and urine, with DMS02
also present but in much smaller concentra-
tions. A small percentage of the original dose
of DMSO is reduced to DMS and exhaled.
Tn appears that the primary route of excre-
tion ofDMSO is through the urine. 8 One and
one-half to two hours after cutaneous ad-
ministration of DMSO, the highest concen-
tration is found in the kidneys, indicating that
the kidney is the organ of excretion. In dogs,
studies indicate that approximately 50 % of a
total dose of DMSO-35S is collected in urine
after 36 hours whether given by oral or in-
travenous administration. 8 When DMSO-35S
is applied cutaneously, only 12 - 25 % of the
total dose is found in the urine collected over a
24 hour period. Only a small fraction of an
original dose of DMSO is excreted in the
feces, regardless of the route of administra-
tion.
The biliary system also appears to play a
role in the excretion of DMSO. In rats ad-
ministered DMSO intravenously, 8 % of the
total dose is recovered in a 24 hour period.
This suggests that a large portion of the
DMSO dose is reabsorbed in the entero-
hepatic circulation.
The odoriferous breath associated with ad-
ministration of DMSO led researchers to in-
vestigate the possibility of pulmonary excre-
tion. It was found that a small amount of
DMSO is reduced to DMS and exhaled in the
breath. Approximately 3-6% of a total
DMSO dose is exhaled in the breath, regard-
less of the route of administration. 3
BIOLOGICAL ACTIONS OF DMSO
AND THEIR CLINICAL
SIGNIFICANCE
Dimethyl sulfoxide has a multitude of bio-
logical actions which have been den10nstrated
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in the laboratory and also under clinical situa-
tions . Many of the pharmacolog~calproperties
of DMSO are still under laboratory investiga-
tion and have not yet been extended to use in
the field of veterinary medicine. However,
with additional research into the potential
uses of DMSO it may prove to have an amaz-
ing diversity of applications in the medical
field.
Membrane Penetration
DMSO readily crosses most tissues of ani-
mals and man with the exception of tooth
enamel and keratinized structures. The exact
mechanism involved in the membrane-pene-
trant action of DMSO has yet to be eluci-
dated. It has been hypothesized that DMSO
substitutes for water in the skin causing a re-
versible configurational change of the skin
protein, thus accounting for the rapid passage
of DMSO through the skin. 11 The ability to
penetrate body membranes and to become
widely distributed throughout the body is ad-
vantageous, especially the ability of DMSO to
transport other pharmacological agents
through the skin and other biological mem-
branes.
Membrane Transport
DMSO can serve as a vehicle for topical
drugs and facilitate their transport through
the skin. DMSO carries substances rapidly
and deeply into the horny layer of the skin. 12
N on-ionized molecules of low molecular
weight are transported through the skin with
DMSO, but substances of high molecular
weight do not pass through the skin with
DMSO to any significant extent. 11 This abil-
ity to enhance percutaneous penetration of to-
pical medications lends itself well to use in
dermatological disorders because the primary
limitation to topical therapy is the skin's pro-
tective characteristics. DMSO has been found
to enhance the penetration of the following
therapeutic agents: Antibacterials, 11 anti-
virals,s estrogens,l1 corticosteriods, anti-para-
sitics, and local anesthetics. In one human
case, DMSO was used to maintain nourish-
ment by percutaneous absorption of nutrients
dissolved in DMSO. 14 Most evidence indi-
cates that DMSO itself, does not have healing
properties in the majority of dermatological
disorders, but its ability to serve as a vehicle
for the transfer of drugs through the intact
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skin and for deposition of these drugs into the
skin is its beneficial effect. 2.12.14
Anti-Inflammation
DMSO apparently has significant anti-
inflammatory properties. Researchers indi-
cate that the anti-inflammatory effect of
DMSO may be due to its ability to scavenge
inflammation-triggering free radicals5 and/or
its ability to inhibit the influx of poly-
morphonuclear cells and monocytes into the
sites of inflammation. 15 One of the most pop-
ular uses of DMSO is for treatment of acute
swelling associated with traumatic injuries.
Another use of DMSO which utilizes its anti-
inflammatory properties is in the treatment of
toxic snake bites. 16 It is thought that use of
DMSO decreases the swelling resulting from
the snake bite, and it also potentiates the ac-
tion of the adn1inistered corticosteroids.
DMSO also decreases the inflammation asso-
ciated with perivascular injections of thiace-
tarsamide sodium. 17 DMSO decreases the
swelling and dissipates this irritating antipara-
sitic, and thus prevents sloughing of sur-
rounding tissues. DMSO is also used in the
treatment regime for otitis externa to reduce
irritation. Treatment of ulcers and wounds is
also augmented by DMSO therapy, in part
due to its anti-inflammatory properties. 18 To-
pical application of DMSO to canine mam-
mary glands reduces swelling and engorge-
ment. 19 DMSO has also been used to relieve
post-operative pain and swelling following
joint and tendon repair procedures. 2o
Analgesia
DMSO alone has analgesic properties, and
when used in conjunction with topical anes-
thetics appears to potentiate their effects.
DMSO reversibly decreases the conduction
velocity of nerves and produces analgesia by
acting on both the peripheral nervous system
and the central nervous system. 21 Subcuta-
neous injection of 10% DMSO can result in a
total loss of central recognition of pain. 11
DMSO produces an analgesic effect compara-
ble to morphine, but it is longer lasting and is
not reversible by administration of nalox-
one. 20 Since it is not reversed by naloxone,
this indicates that opiate receptors are not in-
valved in DMSO-induced analgesia. DMSO
can also induce total anesthesia of an animal
when injected into the cerebral spinal fluid
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without apparent adverse reactions. 11 How-
ever, clinical application of this method of an-
esthesia is impractical.
Effects on Connective Tissue
DMSO decreases the concentration of col-
lagen and its metabolites and also reduces the
pathogenic deposition of collagen in response
to injury. Experimentally, DMSO injected in-
traperitoneally will decrease the incidence of
intestinal adhesions. 11 This Inay prove useful
for post-operative treatment of gastrointes-
tinal surgery. Studies involving the use of
DMSO for treatment of collagen-related
arthritis resulted in conflicting results 11 ,23.24
and requires further studies to determine the
efficacy of DMSO in treating this disorder.
Effect on Bacteria, Fungi,
and Viruses
DMSO exhibits a remarkable inhibitory ef-
fect on a wide range of bacteria, fungi, and
both RNA and DNA viruses. 11 The bacteriq-
static effect of DMSO may occur due to a loss
of RNA conformational structure required for
protein synthesis. 11 Pre-treatment with
DMSO restored and increased the sensitivity
of antibiotic-resistant strains of bacteria and
increased the sensitivity of bacteria in general
to antibiotic treatment. 11 This characteristic
of DMSO may prove to be valuable.
Diuresis
DMSO has been shown to be an effective
diuretic due to an increase in the urinary ex-
cretion of sodium and potassium. This
diuretic effect may prove valuable in treating
cases of central nervous system trauma be-
cause the diuretic effect of DMSO is effective
in decreasing intracranial pressure. 25 In man,
intravenous DMSO is more effective than
mannitol, urea, cortisone, or barbiturates for
reducing intracranial pressure associated with
severe head injuries. 26
Vasodilation
DMSO has potent histamine-releasing
properties which result in significant vasodila-
tion. 11 This vasodilatory effect may be useful
in decreasing edema, improving circulation in
localized areas, and increasing the absorption
of other drugs. DMSO vasodilation increases
the cortical and spinal blood flow, thus reduc-
ing the edema resulting from acute cranial
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and spinal cord trauma. 25 .27 Experimentally,
DMSO has been used to treat intestinal,28 re-
nal,29 and cerebral ischemia. 3o.31
Action on Free-Radicals
DMSO has the ability to scavenge free-rad-
icals, especially hydroxyl radicals and hydro-
gen atoms. S The carcinogenic effect of many
organic compounds is related to the formation
of free-radical intermediates. It has been
shown that DMSO causes a significant inhibi-
tion of promoters of neoplasia, with reduction
of both tumor rate aIJ.d yield.~ D_MSO has also
been shown to protect tissues and cells against
radiation damage. This protective effect is due
to inhibition of hydroxy radicals by DMSO.
The scavenging of free-radicals also aids in
reduction of pain induced by inflammation. 2
DMSO has been shown to increase the effec-
tivepess of griseofulvin and potentiate the ac-
tion of digitoxin. 11 This is clinically important
when using DMSO concomitantly with other
therapeutic agents.
TOXICITY OF DMSO
The potentially toxic effects of DMSO is the
subject which virtually brought clinical inves-
tigations of DMSO to a standstill, but it is
interesting to note that DMSO is of such low
toxicity that grams per kilogram are used to
measure toxicity instead of milligrams per ki-
logram as in the case of most other drugs. The
toxic effects of DMSO vary with concentra-
tion, dosage, and route of administration.
Common complaints associated with the
use of DMSO are the garlic-like breath odor,
erythema, dryness, occasional pruritus asso-
ciated with cutaneous administration, and di-
arrhea. In humans, headache,32 nausea, seda-
tion, and less frequently, dizziness2s ,26 are
reported and it is assumed that animals may
experience similar phenomena. U rea-modi-
fied DMSO moderates some of these side ef-
fects. Urea-modified DMSO consists of 60-
parts DMSO, 20-parts urea, and 20-parts
water. 6 This formula decreases the garlic or
sulfur odor in the breath and the cutaneous
irritation, pruritus and dryness.
Since the potential for systemic toxicity is
the greatest with intravenous administration
of DMSO, the LD50 has been determined for
several species and are in the range of 2.5-
8.9g/kg body weight. 33 Symptoms at near le-
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thaI doses were similar in all species investi-
gated and include spontaneous motor activity,
tremors, muscular weakness,' prostration,
transient convulsions, dyspnea, pulmonary
edema, and hemorrhage. 33 The oral LD50 of
DMSO is higher than the intravenous LD50
and is approximately 109/kg body weight. 34
With intravenous administration of DMSO
it was found that there is no increased toxicity
with repeated daily dosing, assuming that the
repeated daily does not exceed the single max-
imum tolerated dose. 35 Damage to blood ves-
sels due to DMSO is directly proportional to
the concentration of DMSO and the number
of repeated injections. The concentration of
DMSO administered intravenously should
not exceed 50% or the injected vessel may be
subject to intimal damage, fibrosis, perivascu-
lar inflammation, and/or intravascular
thrombi. 3s However, no necrosis or sloughing
of the blood vessel occurs. At or above the
maximum tolerated dose there is a transient
increase in respiratory rate, an increase in
diuresis, and evidence of hemoglobinuria and
bilirubinuria which are a direct result of
erythrocyte damage and subsequent release of
hemoglobin. 35
Rapid in travenous administration of
DMSO can induce seizures. 21 Local tissue
reactions to subcutaneous or intramuscular
injections are directly related to the concen-
tration and total amount of DMSO injected.
Reported responses to these injections include
inf1~mmatory, hemorrhagic, gelatinous, and
edematous tissue reactions, but there is no
abscess formation, necrosis, or sloughing. 35
Intradermal injections of undiluted DMSO
cause an intense local vasoconstriction fol-
lowed by hemorrhage and necrosis,35 and
therefore, should be avoided.
Most biochemical changes associated with
the administration of DMSO are related to
the damage incurred by the red blood
cells. 35 ,36 This direct hemolytic effect is dose-
related and is seen with intravenous DMSO
in high concentration or high dosage rate.
Very high doses of oral DMSO cause hemor-
rhagic gastroenteropathy. Hemolysis results
in a reversible anemia with a reduction in he-
moglobin in the circulating blood, hemoglobi-
nuria, hematuria, and bilirubinuria. As a re-
sult of red blood cell damage, reticulocytosis
and increased erythroid activity in the spleen
and bone marrow are often observed.
Iowa State Veterinarian
In spite of the dose-related hemolysis and
subsequent hemoglobinuria associated with
high concentrations of intravenous DMSO,
there is no decrease in renal function and in
general, no evidence of renal structural
changes. 36 Some reports indicate the presence
of a mild tubular nephrosis,33 but there are no
reports of nephrotoxic tubular damage. Also,
there are no urine sediment abnormalities,
and no increases in urine protein or glucose.
Liver damage with ~igh doses of DMSO
consists of fatty degeneration, cloudy swell-
ing, granulation of parenchymal cytoplasm,
and inflammation in the portal spaces. 33.35
Other changes include hemolyzed red blood
cells in the hepatic sinusoids, cytoplasmic
fragmentation of the Kupffer cells, and hemo-
siderin granules in the interstitium.
Pulmonary changes associated with the
conventional administration of DMSO are
not common but with near-lethal doses of
DMSO, development of pulmonary edema
can occur. 35 The pathogenesis of pulmonary
edema is related to a decreased heart rate and
blood pressure, vascular distention, and stasis
of blood.
Teratogenic effects of DMSO appear to be
n1inimal unless extraordinarily high doses of
DMSO are administered. The most definite
teratogenic effects are seen in the hamster and
the chicken. 35 In the hamster, the teratogenic-
ity of DMSO is directly related to the stage of
development of the embryo when DMSO is
administered. Direct injection of DMSO into
the chick embryo results in fetal abnormali-
ties, but injection of DMSO into the yolk sac
does not produce any teratogenic effect. Rab-
bits treated with very high doses of DMSO
demonstrate a reduction in embryo viability. 35
Administration of DMSO in high doses, to
both male and female rats prior to mating,
does not cause any reduction in fertility nor is
it associated with any teratogenic effects. 33
The major concern associated with adminis-
tration of DMSO to gravid animals is the do-
sage given, but it is unlikely in a clinical situa-
tion that such high doses would be dispensed.
The topical route of application of DMSO
appears to be the least toxic. The most impor-
tant aspect of the cutaneous toxicity ofDMSO
involves local tissue reactions. DMSO passes
through the skin fairly rapidly and causes va-
sodilation and erythema proportional to the
concentration of DMSO applied. Cutaneous
vol. 46) No. 2
application of high concentrations of DMSO
solutions exaggerate the hydroscopic effects of
DMSO, depriving the tissues of water. 33 Dogs
and monkeys treated vvith 90% Dl\1S0 over
an extended period exhibit a slight hyperkera-
tosis of the skin with no other significant his-
tological changes in the skin. 35 In humans,
80 % DMSO applied topically results in a sig-
nificant incidence of eosinophilia, attributed
to the cutaneous histamine-releasing effect of
DMSO. 33
Cutaneous administration of DMSO with
occulusive bandages may cause a papillovesi-
cular reaction which leads to inflammation
and epidermal death. 37 Although these are not
permanent changes, occulusive bandaging
should be avoided when using topical DMSO.
The transport and penetrant properties of
DMSO impose a hazard to the cutaneous ad-
ministration of DMSO. DMSO has the capa-
bility to enhance the absorption of topical
medications and other materials into the skin,
and therefore, any other medication or com-
pound present on the skin should be removed
prior to cutaneous application of DMSO.
DMSO and its metabolites will not accu-
mulate in the tissues, and no delayed toxicity
to DMSO has been reported. 35 In animals
treated with intradermal DMSO for 3 weeks,
no signs of sensitization were noted when
challenged with an intradermal dose of
DMSO. 35 Therefore, any toxic effects of
DMSO will most likely be observed during or
immediately following DMSO therapy.
Administration of DMSO causes the corti-
cal fibers of the lens of the eye to become less
relucent than normal and this change results
in the production of a refractive error and
myopia. 34 The severity of this change is
directly related to the length of administration
of DMSO and the concentration of DMSO
used. Clinically, severely affected animals
have an opalescence in the center of the lens
although the lens remains optically clear. The
pathogenesis of the DMSO-induced lenticular
change is not known. DMSO does not accu-
mulate in the lens but following chronic ad-
ministration, DMSO can be found in the cor-
nea, aqueous humor, and vitreous body. 33
These lenticular changes, once established,
persist for long periods of time.
In summary it is apparent that the toxicity
of DMSO is minimal when used in clinically
normal doses and concentrations. The toxic
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!effects are most frequently seen in abnormally
Ihigh experimental doses and concentrations.
lIn view of the toxicological evidence, certain
precautions should be exercised when using
DMSO, including proper and safe doses, con-
centrations, and routes of administration of
DMSO and proper patient selection. Patients
with a history of blood disorders, renal dis-
ease, seizures, pregnancy, dermal disorders,
hepatic disease, pulmonary disease or ocular
disease should be screened carefully, and it
should be ascertained that the beneficial ef-
fects of DMSO outweigh the possible detri-
mental effects.
CURRENT STATUS
Since 1972 there have only been two New
Drug Applications (NDA) for DMSO. 4 In
1978 an NDA for the use of 50% DMSO in-
travesicularly for interstitial cystitis was ap-
proved. The NDA for the use of DMSO in
the treatment of scleroderma was rejected be-
cause the data did not demonstrate conclu-
sively the efficacy of DMSO in treating this
disorder. Thus, the only FDA approved use of
DMSO in humans is for treatment of intersti-
tial cystitis. Currently, there are no NDA:s
pending for DMSO.
For use in veterinary medicine, DMSO is
labeled for use in dogs and horses for treat-
ment of acute swelling caused by trauma. It is
recommended for topical use only. The label
includes the restriction that DMSO is not to
be used in horses to be slaughtered for food.
Veterinarians may use DMSO for treatment
of other disease processes but must inform the
client that this is not an approved use of
DMSO, and the individual practitioner is lia-
ble for any untoward consequences.
CONCLUSION
While DMSO is certainly not a "miracle"
drug, its potential for beneficial use in the
medical field is probably underrated. Due to
restrictions imposed by the FDA almost
twenty years ago, progress in the use of
DMSO in clinical situations has been slow.
Although the chemical structure of DMSO is
relatively simple, it is capable of a diverse
range of chemical reactions which probably
attribute to its wide variety of biological ac-
tions. The ability of DMSO to penetrate most
biological membranes and disperse itself
widely throughout the body and its ability to
transport other drugs in a similar manner cer-
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tainly has important therapeutic implications.
The anti-inflammatory properties of DMSO
are currently the most frequently utilized
clinically. The numerous biological actions of
DMSO require further laboratory and clinical
investigations if these properties are to be uti-
lized to their maximum potential. The biolog-
ical actions of the metabolites of DMSO also
require further research to determine their
specificity of action. The use of DMSO me-
tabolites may be the answer to decreasing the
adverse side effects of DMSO therapy. The
toxicity of DMSO appears to be minimal, and
while the FDA is concerned with the ocular
effects of DMSO, the importance of this ad-
verse side effect in domestic animals may be
questionable when compared to the potential
beneficial effects of Dl\r1S0 treatment. It ap-
pears that DMSO has important implications
in treatment of a wide range of medical disor-
ders, but these biological effects require much
more extensive investigations. Therefore, in-
discriminate use ofDMSO is contraindicated.
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